APCs induce T cell priming, where activated T cells recognize tumor‐specific antigens and incite tumor‐targeted cytotoxicity.[7] In clinical trials, single agent ICIs targeting CTLA‐4 or PD‐1/PD‐L1 did not improve outcomes in unselected patients with PDAC.[8] In contrast, agonistic agents acting as host immune response initiator, such as CD40, ICOS, and 4‐1BB, could serve as a potent immunotherapy avenue for PDAC therapy. This evidence concerns the gene TNFRSF9 and neoplasm.